Orphanet: Efficacy and Safety of Velcade Plus Dexamethasone VD, VD Cyclophosphamide or VD Plus Lenalidomide in MMY Multiple Myeloma Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD Phase II coordination
x

Cerca un network

* (*) campo obbligatorio

Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY (Multiple Myeloma) Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD (Phase II) (coordination)

Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY (Multiple Myeloma) Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD (Phase II) (coordination)

  • Tipo di network : Sperimentazioni cliniche internazionali
  • Distribuzione geografica : Europeo
  • Ente(-i) finanziatore(-i) : -
  • Sponsor : Janssen-cilag international n.v.
  • Sito web
Ultimo aggiornamento: Marzo 2011

Informazioni supplementari

Tutte le informazioni presenti nel sito non sostituiscono in alcun modo il giudizio di un medico specialista, l'unico autorizzato ad effettuare una consulenza medica ed esprimere un parere medico.